Sciencast Management LP Boosts Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Sciencast Management LP increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 137.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,317 shares of the medical research company’s stock after buying an additional 1,922 shares during the period. Sciencast Management LP’s holdings in Thermo Fisher Scientific were worth $1,726,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Millstone Evans Group LLC bought a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $1,499,000. 1620 Investment Advisors Inc. boosted its holdings in shares of Thermo Fisher Scientific by 7.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 671 shares of the medical research company’s stock worth $349,000 after acquiring an additional 48 shares during the period. One Charles Private Wealth Services LLC boosted its holdings in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. One Charles Private Wealth Services LLC now owns 499 shares of the medical research company’s stock worth $260,000 after acquiring an additional 20 shares during the period. Lee Danner & Bass Inc. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $60,000. Finally, Ballast Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific by 10.5% in the fourth quarter. Ballast Advisors LLC now owns 1,923 shares of the medical research company’s stock worth $1,000,000 after acquiring an additional 182 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the transaction, the chief financial officer now owns 27,296 shares in the company, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock valued at $13,106,062 in the last 90 days. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.1 %

TMO opened at $518.04 on Friday. The company has a market cap of $195.44 billion, a P/E ratio of 31.34, a P/E/G ratio of 2.99 and a beta of 0.79. The business’s 50-day moving average price is $546.15 and its 200-day moving average price is $556.26. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.41%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Bank of America cut their price target on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a report on Friday, December 13th. UBS Group raised their price target on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a report on Friday, January 31st. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Citigroup dropped their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Finally, Sanford C. Bernstein raised Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a research note on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $653.23.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.